LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Prothena Corp PLC

Cerrado

SectorSanidad

5.39 6.52

Resumen

Variación precio

24h

Actual

Mínimo

5.01

Máximo

5.43

Métricas clave

By Trading Economics

Ingresos

-2.2M

-60M

Ventas

705K

2.8M

BPA

-1.12

Margen de beneficios

-2,128.536

Empleados

163

EBITDA

-682K

-65M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+380.04% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-495M

251M

Apertura anterior

-1.13

Cierre anterior

5.39

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

167 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Prothena Corp PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jun 2025, 20:45 UTC

Ganancias

Broadcom 2Q Sales Climb on Booming AI Demand

5 jun 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5 jun 2025, 23:44 UTC

Charlas de Mercado

Gold Edges Higher on Weak U.S. Data -- Market Talk

5 jun 2025, 23:30 UTC

Charlas de Mercado

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5 jun 2025, 21:32 UTC

Ganancias

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

5 jun 2025, 20:45 UTC

Ganancias

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 jun 2025, 20:24 UTC

Ganancias

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 jun 2025, 20:15 UTC

Ganancias

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5 jun 2025, 20:15 UTC

Ganancias

Broadcom 2Q Rev $15B >AVGO

5 jun 2025, 20:15 UTC

Ganancias

Broadcom 2Q Net $4.97B >AVGO

5 jun 2025, 20:15 UTC

Ganancias

Broadcom 2Q Adj EPS $1.58 >AVGO

5 jun 2025, 20:15 UTC

Ganancias

Broadcom 2Q EPS $1.03 >AVGO

5 jun 2025, 20:15 UTC

Ganancias

Broadcom Sees 3Q Rev $15.8B >AVGO

5 jun 2025, 20:11 UTC

Adquisiciones, fusiones, absorciones

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5 jun 2025, 20:11 UTC

Adquisiciones, fusiones, absorciones

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5 jun 2025, 20:11 UTC

Adquisiciones, fusiones, absorciones

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5 jun 2025, 19:22 UTC

Charlas de Mercado

Oil Futures Resume Upward Moves -- Market Talk

5 jun 2025, 19:00 UTC

Charlas de Mercado

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5 jun 2025, 18:32 UTC

Charlas de Mercado

Gold Slips After Trump-Xi Call -- Market Talk

5 jun 2025, 18:26 UTC

Ganancias

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5 jun 2025, 18:06 UTC

Charlas de Mercado

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5 jun 2025, 16:30 UTC

Adquisiciones, fusiones, absorciones

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5 jun 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

5 jun 2025, 16:18 UTC

Charlas de Mercado

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

5 jun 2025, 16:12 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

5 jun 2025, 16:12 UTC

Charlas de Mercado

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5 jun 2025, 16:03 UTC

Charlas de Mercado

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5 jun 2025, 15:49 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Prothena Corp PLC previsión

Precio Objetivo

By TipRanks

380.04% repunte

Estimación a 12 Meses

Media 24.29 USD  380.04%

Máximo 81 USD

Mínimo 4 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Prothena Corp PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

9 ratings

4

Comprar

4

Mantener

1

Vender

Puntuación técnica

By Trading Central

N/A / 7.35Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

167 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.